Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants

Clinical Infectious Diseases

Volumn 52, Issue 8, 2011, Pages 1069-1076

  Fogel, Jessica ^a   Li, Qing ^c   Taha, Taha E ^b   Hoover, Donald R ^e   Kumwenda, Newton I ^b   Mofenson, Lynne M ^d   Kumwenda, Johnstone J ^g   Fowler, Mary Glenn ^a,f   Thigpen, Michael C ^f   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LACTATION; MALAWI; MALE; NEWBORN; NEWBORN INFECTION; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANK SUM TEST; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREAST FEEDING; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PLASMA; POSTPARTUM PERIOD; RNA, VIRAL;

EID: 79953898239     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir008     Document Type: Article

References (26)

1. Mofenson LM. Protecting the next generation-eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362:2316-2318.
2. World Health Organization (WHO). HIV and infant feeding. Rapid advice. 2009. Available at: http://whqlibdoc.who.int/publications/2009/ 9789241598873-eng.pdf. Accessed 5 March 2010.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS, 2009. Available at: http://data.unaids.org/ pub/Report/2009/JC1700-Epi-Update-2009-en.pdf. Accessed 6 June 2010.
4. Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21:83-93.
5. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315-323.
6. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended anti-retroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129. (Pubitemid 351962035)
7. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313.
8. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
9. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
10. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52:406-416.
11. Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis 2009; 200:1490-1497.
12. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141. (Pubitemid 351962036)
13. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198:1075-1082.
14. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009; 4:e4096.
15. Persaud D, Bedri A, Ziemniak C, et al. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV-transmission. AIDS Res Hum Retroviruses 2011. E-Pub ahead of print.
16. Lidstrom J, Li Q, Hoover DR, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24:381-386.
17. McSherry GD, Shapiro DE, Coombs RW, et al. The effects of zidovu-dine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr 1999; 134:717-724. (Pubitemid 30186815)
18. Zeh C, Weidle P, Nafisa L, et al. Emergence of HIV-1 drug resistance among breastfeeding infants born to HIV-infected mothers taking antiretrovirals for prevention of mother-to-child transmission of HIV: the Kisumu Breastfeeding Study, Kenya (abstract #84 LB). 15th Conference on Retroviruses and Opportunistic Infections., Boston, MA, 3-6 February 2008.
19. Lidstrom J, Guay LA, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate highly active antiretroviral therapy (HAART) post-partum (abstract #920). 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 16-19 February 2010.
20. Lidstrom J, Kumwenda N, Kafulafula G, et al. Antiretroviral treatment of HIV-infected women can induce multi-class drug resistance in their breastfeeding infants. Antivir Ther 2009; 14(Suppl 1):135.
21. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-1176.
22. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727. (Pubitemid 41193069)
23. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
24. World Health Organization (WHO). Report of the WHO Technical Reference group, Paediatric HIV/ART Care Guideline Group Meeting. 2009. Available at: http://www.who.int/hiv/pub/paediatric/WHO- Paediatric-ART-guideline-rev-mreport- 2008.pdf. Accessed 6 June 2010.
25. Bae WH, Wester C, Smeaton LM, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 2008; 22:1633-1640.
26. World Health Organization (WHO). Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Rapid advice. 2009. Available at: http://www.who.int/hiv/pub/mtct/ rapid-advice-mtct.pdf. Accessed 28 May 2010.